SynthesisBMC psychiatry2025
Cognitive behavioral therapy for the management of cardiometabolic disease risk factors; a systematic meta-review of meta-analyses.
Synthesis in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Psychobehavioral Assessment and Brief Cognitive-Behavioral Therapy in Resistant Arterial Hypertension: A Feasibility-Oriented Pilot Study Within a Precision Medicine Framework.Journal of personalized medicine · 2026Article
- Digital Cognitive Behavioral Therapy for Cardiac Anxiety After Myocardial Infarction: Effects on Disease-Specific Health Status-Detailed Methods and Protocol.JACC. Advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCognitive behavioral therapy (CBT) has been suggested to patients with cardiometabolic abnormalities to change dysfunctional lifestyle and behavioral patterns and enhance psychological health. This systematic review of meta-analyses aimed to discuss current research findings regarding CBT approaches for the risk management of cardiometabolic disease and related risk markers.
methodsA literature search was conducted in MEDLINE (via PubMed), Scopus, EMBASE, PsycINFO, CINAHL and the Cochrane Database of Systematic Reviews databases, for meta-analyses published between January 2010 and December 2024 examining the association between CBT and cardiometabolic disease. Meta-analyses in English language, studying populations with cardiometabolic abnormalities, and examining CBT's effectiveness on risk factors of cardiometabolic disease, were retrieved.
resultsSixteen meta-analyses were included. Findings suggest that CBT is effective in decreasing depressive symptoms and anxiety. Less evidence is available regarding the other risk-markers of cardiometabolic disease, as well as for improving quality of life and reducing risk of recurrent cardiovascular events. Conflicting findings exist regarding CBT's impact on managing blood pressure, blood lipids, and diabetes-related biomarkers. The results should be viewed with caution, as the studies included have several methodological shortcomings, such as small samples, high heterogeneity across studies, and low quality.
conclusionsCurrent literature suggests that CBT seems a promising approach in disrupting the path through which psychological factors contribute to cardiometabolic disease development, although further studies are need.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.